Published in J Clin Virol on October 01, 2001
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
S100β as a novel and accessible indicator for the presence of monocyte-driven encephalitis in AIDS. Neuropathol Appl Neurobiol (2012) 0.87
Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. Am J Med Genet B Neuropsychiatr Genet (2012) 0.84
HIV-associated deficits in action (verb) generation may reflect astrocytosis. J Clin Exp Neuropsychol (2009) 0.83
Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J Neurovirol (2011) 0.81
Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. J Neurovirol (2016) 0.76
Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. AIDS (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
The AIDS dementia complex. J Infect Dis (1988) 2.77
Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med (1992) 2.65
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem (2001) 1.79
Association between HIV distal symmetric polyneuropathy and Mycobacterium avium complex infection. J Neurol Neurosurg Psychiatry (1996) 1.44
Kaposi's sarcoma and protection from AIDS dementia complex. AIDS (1998) 1.30
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol (1992) 1.22
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology (2007) 1.21
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol (2005) 1.21
Undifferentiated mouse mesenchymal stem cells spontaneously express neural and stem cell markers Oct-4 and Rex-1. Cytotherapy (2006) 1.19
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol (2001) 1.17
HTLV-I-associated myelopathy associated with blood transfusion in the United States: epidemiologic and molecular evidence linking donor and recipient. Neurology (1991) 1.14
Neurocytotoxity of quinolinic acid in human brain cultures. J Neurovirol (1995) 1.13
Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J Neurochem (1994) 1.06
Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem (2002) 1.05
AIDS dementia complex and HIV-1 infection: a view from the clinic. Brain Pathol (1991) 1.05
The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med (2008) 1.01
A screening algorithm for HIV-associated neurocognitive disorders. HIV Med (2010) 1.00
Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep (2000) 0.99
The AIDS dementia complex and HIV-1 brain infection: a pathogenetic model of virus-immune interaction. Res Publ Assoc Res Nerv Ment Dis (1990) 0.97
Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology (1997) 0.96
Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res (1997) 0.95
Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1990) 0.94
Myositis associated with a newly described microsporidian, Trachipleistophora hominis, in a patient with AIDS. J Clin Microbiol (1996) 0.94
Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS (1998) 0.93
IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res (2001) 0.93
Neural transplantation of human MSC and NT2 cells in the twitcher mouse model. Cytotherapy (2006) 0.92
Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med (2007) 0.91
Could antiretroviral drugs be effective in multiple sclerosis? A case report. Eur J Neurol (2011) 0.90
Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection. J NeuroAIDS (1996) 0.90
The management of the neurological complications of HIV infection and AIDS. AIDS (1988) 0.86
Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry (1997) 0.85
Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults? HIV Med (2011) 0.85
Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT(1A) receptors. Br J Pharmacol (2008) 0.85
Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 0.85
HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet (1998) 0.84
Update on HIV-related neurological illness. AIDS (1991) 0.84
Diagnosis of Wernicke's encephalopathy. Aust N Z J Med (1986) 0.82
Kynurenine pathway metabolism in human astrocytes. Adv Exp Med Biol (1999) 0.82
Dissociation of AIDS-related vacuolar myelopathy and productive HIV-1 infection of the spinal cord. Neurology (1989) 0.81
Intractable headache as the presenting complaint of AIDS-related lymphoma confined to bone. J Acquir Immune Defic Syndr (1994) 0.81
Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol (2007) 0.80
Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology (2010) 0.80
Human T-lymphotropic virus type I-associated myelopathy in patients with the acquired immunodeficiency syndrome. Hum Pathol (1992) 0.80
Clinical Markers of the Presence of Dementia and Neuropsychological Impairment in HIV Infection. J NeuroAIDS (1996) 0.79
Stereotactic biopsy of cerebral lesions in acquired immunodeficiency syndrome. J Clin Neurosci (1995) 0.79
Pursuit eye movement dysfunction in HIV-1 seropositive individuals. J Psychiatry Neurosci (1991) 0.79
Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 infection. J Neurochem (1992) 0.77
Anomalies in Nef expression within the central nervous system of HIV-1 positive individuals/AIDS patients with or without AIDS dementia complex. J Neurovirol (1998) 0.77
Cerebral perfusion scanning in treating AIDS dementia: a pilot study. J Nucl Med (1998) 0.77
Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy. Neurology (2000) 0.76
Another retroviral disease of the nervous system: chronic progressive myelopathy due to HTLV-1. N Engl J Med (1988) 0.76
Human immunodeficiency virus in brain and correlation with dementia. Ann Neurol (1996) 0.76
Markers of AIDS dementia complex: the role of cerebrospinal fluid assays. AIDS (2001) 0.76
Alcohol and brain damage. Br J Addict (1984) 0.76
HIV dementia. Neurology (1994) 0.75
HTLV-I and HIV infection of the CNS in tropical areas. J Neurol Neurosurg Psychiatry (2001) 0.75
Does HHV-8 have a neuroprotective role on the development of HIV encephalopathy? Neurology (2000) 0.75
HIV nomenclature. Neurology (1992) 0.75
Prognosis of patients ... myelopathy of unknown origin. Aust N Z J Med (1990) 0.75
Neurological efficacy of stavudine, zidovudine, and lamivudine. Lancet (1998) 0.75
Evaluation and management of intracranial mass lesions in AIDS: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (1998) 0.75
Neurological manifestations of HIV-1 infection. AIDS (1991) 0.75
Acute encephalopathy caused by human immunodeficiency virus apparently responsive to zidovudine. Med J Aust (1990) 0.75
MS-like leukoencephalopathy in HIV-1. Neurology (1991) 0.75
Managing HIV. Part 5: Treating secondary outcomes. 5.4 HIV-induced neurological disease. Med J Aust (1996) 0.75
Pathogenetic implications of neuropathological findings in the AIDS dementia complex. Psychopharmacol Bull (1988) 0.75
Managing HIV. Part 5: Treating secondary outcomes. 5.5 HIV and opportunistic neurological infections. Med J Aust (1996) 0.75
HIV-1 gp120 does not induce Quinolinic acid production by macrophages. J Neurovirol (1997) 0.75
Raltegravir resistance in the cerebrospinal fluid. Infection (2013) 0.75